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Abstract 
Background and aims:   In Scotland, Hepatitis B virus (HBV) vaccination for all prisoners was 
introduced in 1999; here, we examine the impact of this programme among people who 
inject drugs (PWID) in the community. This study aimed to compare rates of HBV vaccine 
uptake before and after implementation of the prison programme and to estimate the 
determinants of vaccine uptake, the levels of ever/current HBV infection and the 
associations between vaccine uptake and ever/current HBV infection. 
Design: Data collected via serial cross-sectional surveys were used to compare the proportion 
who reported being vaccinated over time. For the 2013-14 survey, rates of ever/current HBV 
infection were calculated and the associations between vaccine uptake and ever/current 
HBV infection were examined using logistic regression. 
Setting: Services providing injecting equipment and drug treatment, and street sites, in 
Glasgow (1993–2002) and across Scotland (2008–2014).  
Participants: More than 10,000 PWID in total were recruited in the surveys.  
Measurements: Participants completed a questionnaire (all years) to ascertain self-reported 
vaccine uptake and provided a blood spot (in 2013-14), tested for HBV core antibodies (anti-
HBc) and surface antigen (HBsAg).  
Findings: Among recent-onset PWID in Glasgow, vaccine uptake increased from 16-20% in 
1993-99 to 52-59% in 2001-2014 (p<0.001). Among all PWID in Scotland, uptake increased 
further from 71% in 2008-09 to 77% in 2013-14 (p<0.001) and was associated with 
incarceration (adjusted odds ratio 2·91, 95% CI 2·23-3·79). The prevalence of anti-HBc and 
HBsAg in Scotland was 2·6% and 0·3%, respectively, among PWID who had commenced 
injecting in the decade since the programme’s introduction. Vaccination was associated with 
reduced odds of ever (0·60, 0·37-0·97) and current (0·40, 0·16-0·97) HBV infection.  
Conclusions: In Scotland, uptake of Hepatitis B virus (HBV) vaccination among people who 
inject drugs (PWID) in the community has increased since the 1999 introduction of universal 
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prison vaccination, and current levels of HBV infection among PWID are low compared 
with other European countries. 
Abstract word count: 300 
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INTRODUCTION 
The Hepatitis B virus (HBV) is a blood-borne virus that can cause serious morbidity, 
including cirrhosis and hepatocellular carcinoma. In areas of low HBV prevalence, injecting 
drug use is one of the main risk factors for acquiring the virus [1]. There are an estimated 12 
million people who inject drugs (PWID) worldwide [2], 6·4 million and 1·2 million of whom 
are estimated to be positive for HBV antibodies (anti-HBc) and HBV surface antigen 
(HBsAg), respectively [1].  
The World Health Organization (WHO) global hepatitis strategy [3]was endorsed at the 
World Health Assembly in May 2016, where countries committed to eliminating HBV as a 
public health threat, with targets to reduce HBV incidence by 95% by 2030 [4]. An effective 
vaccine to prevent HBV infection is available and universal vaccination of infants had been 
implemented in 184 countries worldwide as of 2014 [5,6]. Consequently, rates of chronic 
infection are extremely low among vaccinated cohorts [7]. Nevertheless, HBV transmission 
among PWID remains a concern given that, for most countries, the birth cohorts that have 
been vaccinated have not reached the average age of injecting onset.  The impact of catch-up 
programmes and additional efforts to target at-risk population groups may be limited by 
inequitable uptake and/or incomplete coverage.  Thus, HBV transmission among PWID is 
ongoing in many countries [8-11]: for example, in the United States, where universal 
vaccination of infants began in 1991 [12], there are currently an estimated 19,000 cases of 
acute HBV infection annually, with 26% of reported cases (with a known risk factor) 
attributable to injecting drug use [13]. In countries of the European Union/European 
Economic Area, injecting drug use accounts for 15% of reported acute HBV cases [14].  
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A minority of countries, including the United Kingdom (UK), have instead taken a targeted 
approach, whereby only selected groups at high risk of exposure to HBV are offered 
vaccination – including PWID [6,15]. High HBV vaccine uptake among PWID can be 
difficult to achieve through community-based programmes [11]. Given that many PWID are 
incarcerated early in their injecting careers, and they frequently transition into and out of 
prison [16], prisons can be ideal settings for public health interventions targeting this hard-
to-reach group.  
HBV vaccination for all prisoners was introduced in Scottish prisons in 1999, following 
regional and prison-related outbreaks of acute HBV among PWID [17]. More than 15 years 
have now elapsed since the introduction of the prison programme and, given the UK is one 
of the few countries that have not implemented universal infant vaccination, there is a 
unique opportunity to evaluate its effectiveness.  
In this study, we consider the evidence that  the Scottish prison vaccination programme was 
associated with changes in uptake of HBV vaccination and markers of HBV infection among 
PWID recruited at community sites across Scotland. Specifically, the aims of this study were 
to (1) compare rates of HBV vaccine uptake before and after implementation of the prison 
programme, (2) to identify the determinants of vaccine uptake (including incarceration), (3) 
to estimate the prevalence of ever and current HBV infection and (4) to estimate the 
association between vaccine uptake and ever/current HBV infection, among PWID in the 
community. To our knowledge, this is the first national study of a universal prison 
vaccination programme in terms of both vaccine uptake and infection among PWID [17,18].  
 
METHODS 
Design 
The study consists of a series of cross-sectional surveys of PWID, initially confined to 
Glasgow then later expanded to cover all of mainland Scotland. The changes in vaccine 
uptake for Glasgow were compared across the surveys. Scotland data were subsequently 
pooled to examine determinants of vaccine uptake. Levels of HBV infection and the 
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association between vaccine uptake and infection were examined at Scotland-level for 2013-
14. 
Study sample 
The surveys were undertaken in Glasgow in 1993, 1994, 1999 and 2001-02, and across 
mainland Scotland (including Glasgow) in 2008-09, 2010, 2011-12 and 2013-14. All surveys 
were undertaken by trained interviewers. Informed consent was obtained from participants 
and the studies were approved by the West of Scotland Research Ethics Service. The survey 
methods have also been described elsewhere [19-22]. 
Glasgow surveys (1993 to 2002) 
The sampling frame consisted of 15 injecting equipment provision (IEP) services, 20 drug 
treatment services and numerous street sites located throughout Glasgow. Recruitment at 
IEP and drug treatment services was rotated by day of the week and time of day to capture 
as representative a sample as possible: all potentially eligible individuals attending these 
sites were approached to participate. Street sites were chosen in areas of high deprivation, 
which were more likely to have a higher prevalence of injecting drug use. Interviewers 
approached each person that passed by, gave a brief description of the study and asked “we 
are looking for injecting drug users, do you know of anyone who may like to take part in the 
study?” The 1993 and 1994 surveys were restricted to people who had injected drugs in the 
two months prior; in 1999, respondents were eligible if they had injected since January 1990. 
Scotland surveys (2008 to 2014) 
The sampling frame in each national survey consisted of approximately 100 IEP sites (some 
of these may also provide drug treatment), which constitutes approximately 40-50% of all 
IEP sites across Scotland. Sites were chosen to be broadly geographically representative of 
the regional administrative health areas (NHS Boards), comprising a mixture of urban and 
rural sites. Interviewers rotated days of the week and times of day at which they recruited 
from the sites; all individuals attending the service were approached to participate. Target 
sample sizes were set for each NHS Board based on existing knowledge of the size of the 
injecting population in each. Recruitment in each NHS Board took place over a period of 
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approximately six weeks, although more or less time may have been required in order to 
achieve the target.  People who had ever injected were eligible for participation (although 
the proportion of respondents who had injected in the last six months was maintained at a 
minimum of 75%). Participants were also asked to provide a blood spot sample for blood-
borne virus testing.  
Laboratory testing 
HBV testing was performed on dried blood spots (DBS) from the 2013-14 survey. Samples 
were tested for anti-HBc; those that tested positive were then tested for HBsAg. DBS were 
eluted using a modified version of a published method [23]. The modifications were two 
3mm discs punched from the DBS and eluted in 200l of PBS/tween 0.05%. The eluates were 
tested on the Abbott Architect i2000sr using the following assays: Architect Hepatitis B core 
II antibody, Architect HBsAg Qualitative II assay and Architect HBsAg Confirmatory assay.  
Low-level HBsAg positive samples that could not be verified by neutralisation on the 
Architect were confirmed using the miniVIDAS HBsAg Ultra assay (bioMérieux). The 
sensitivity of the DBS method (compared to plasma) for anti-HBc and HBsAg detection is 
89·8% (95% CI 77·8-96·6%) and 100% (95% CI 90·5 – 100%), respectively.  The specificity for 
anti-HBc and HBsAg DBS testing is 100% (95% CI 81·5-100%) and 81·8% (95% CI 59·7-94·8%), 
respectively.  The sensitivity and specificity of HBsAg confirmation testing was 100% (95% 
CI 90·0-100%). Individuals who were anti-HBc positive were considered to be ‘ever infected’; 
past infection was defined as being anti-HBc positive and HBsAg negative; and current 
infection was defined as being anti-HBc and HBsAg positive.  
Statistical analysis 
Trends in vaccine uptake  
The proportions of respondents reporting having been vaccinated (received at least one 
dose), having received 3+ doses of the vaccine, and having been vaccinated in various 
settings were compared across the surveys. This was done separately for Glasgow and 
Scotland. Chi-square tests and p-values were calculated. 
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(i) Glasgow 
The proportions above were compared for Glasgow across the time period 1993 through 
2014.  The data from the Scotland surveys (2008-09 to 2013-14) were restricted to those 
recruited in Greater Glasgow & Clyde who had been injecting for less than five years and 
who had injected in the last six months (while it was not possible to restrict to the last two 
months, we looked at restricting to the last month and this made no difference to the 
results). This was done to enable a valid comparison, given the different eligibility criteria 
applied in the Glasgow surveys (see above). In this analysis, the 2008-09 to 2013-14 data 
were collapsed, as it was found not to have changed across these four surveys.  
(ii) Scotland 
These same proportions described above were also compared across the four national 
surveys for all PWID respondents.  
Determinants of vaccine uptake  
The difference in self-reported vaccine uptake across the national surveys (2008-09 to 2013-
14), and according to whether ever incarcerated, was assessed using logistic regression 
adjusted for potentially confounding factors (gender, age at interview, time since onset of 
injecting, and ever prescribed methadone). These analyses were restricted to those with less 
than ten years since injecting onset, the rationale being that these individuals had 
commenced injecting following the introduction of the prison programme. It was not 
feasible to take account of variation across the hundreds of sites where recruitment took 
place; however, we considered potential clustering by recruitment region (i.e. NHS Board 
areas, which are administrative authorities of the Scottish health service who manage local 
services for PWID, including prevention of blood-borne viruses). To achieve the latter, a 
multi-level framework was applied to the logistic regression model to take into account 
potential variation by NHS Board. 
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Prevalence of ever and current HBV infection 
For the 2013-14 survey, the prevalence of ever infection (anti-HBc positivity) and current 
infection (i.e. those positive for anti-HBc and HBsAg) were calculated for all respondents and 
for those with less than 10 years since onset of injecting. 
Association between HBV vaccination and infection 
Given that vaccination may not have an impact if it is delivered after infection has occurred, 
it is important to demonstrate this effect. Among participants whose DBS samples had been 
tested for HBV, the association between having been vaccinated for HBV (self-reported) and 
ever infection was explored. Potential confounding factors (gender, age, time since onset of 
injecting and having been incarcerated) were identified a priori, and fitted into a logistic 
regression model with the dependent and independent variables. A multi-level model, to 
take into account clustering by NHS Board (as described above) was applied. 
A similar approach to that described above was used to explore the association between 
HBV vaccination and current HBV infection.  Currently infected individuals were compared 
to those negative for anti-HBc. The same confounding factors listed above were examined in 
multivariable models. While it was not possibly to apply a multi-level model due to too few 
observations per cluster, NHS Board was included in the model as a potential confounder 
(and collapsed into Greater Glasgow & Clyde NHS Board vs. elsewhere).Analyses were 
undertaken in SPSS version 21, EpiInfo 7 and R version 3.2.3. 
RESULTS 
Trends in vaccine uptake (Glasgow 1993-2014) 
Among recent-onset PWID in Glasgow, there was a significant upward trend (p<0·001) in 
vaccination uptake across the period beginning prior to introduction of the prison 
programme (16% in 1993) up until the more recent surveys (59% in 2008-14, see Table 1 and 
Figure 1). Among those vaccinated, the proportion who reported receiving 3+ doses of the 
vaccine increased from 62% to 81% (p<0·001) between 2001-02 and 2008-14. Since the 
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introduction of the prison programme, prisons were where the largest proportion of 
vaccinations took place (56% and 40% of vaccinations in 2001-02 and 2008-14, respectively). 
[insert Figure 1 and Table 1 here] 
Trends in vaccine uptake (Scotland 2008-14) 
At the Scotland level, there was a significant increase (p<0·001) in self-reported vaccine 
uptake across the four surveys, from 71% to 77% (Table 1). Among those who reported 
having been vaccinated, there was also a significant increase in the proportion reporting 
having received 3+ doses (from 77% to 83%, p<0.001). Although small changes occurred in 
general practice and drug treatment settings, the largest proportion of vaccinations took 
place in the prison setting (41% in 2013-14).  
Determinants of vaccine uptake (Scotland 2008-14) 
Among those who had been incarcerated since their injecting debut, 83% had been 
vaccinated for HBV, as compared with 58% of those who had not been incarcerated (Table 
2).  After adjustment, the following were significantly associated with vaccine uptake: aged 
>35 years at interview (with this group having lower uptake, as compared to those aged ≤25; 
time since onset of injecting (with those who had been injecting longer having higher odds 
of vaccine uptake); having been prescribed methadone and having been incarcerated (with 
both prescribed methadone and past incarceration being associated with approximately 3-
fold increased likelihood of vaccine uptake). 
[insert Table 2 here] 
Prevalence of ever and current HBV infection (Scotland 2013-14) 
At the Scotland level, the prevalence of anti-HBc was 9% (210/2322) and the prevalence of 
HBsAg was 0·9% (22/2322).  Among PWID who had commenced injecting in the previous 
ten years, the prevalence of anti-HBc and HBsAg was 2·6% (23/872) and 0·3% (3/871), 
respectively. 
Association between HBV vaccination and infection (Scotland 2013-14) 
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After adjustment for potentially confounding factors, having been vaccinated for HBV was 
associated with a lower odds of being anti-HBc positive, as compared to non-vaccinees 
(Table 3). We also examined separately the odds of anti-HBc positivity among those 
vaccinated outside of prison and those vaccinated in prison and found that the AORs for the 
latter and the former were 0.61 (95% CI 0.40-0.94) and 0.57 (0.31-1.06), respectively, relative 
to those never vaccinated.  
[insert Table 3 here] 
Those who had been vaccinated for HBV were also significantly less likely to have a current 
HBV infection, after adjustment for potential confounders (Table 4). 
[insert Table 4 here] 
DISCUSSION 
We found that HBV vaccination uptake among recent-onset PWID has continued to increase 
since the period before, and shortly after, the introduction of universal prison vaccination, 
and that vaccination is associated with a reduced risk of HBV infection. 
While the pre-prison programme data correspond to Glasgow, it is reasonable to assume 
that the trend will have been replicated across Scotland, given the parallels between the 
Glasgow and Scotland data (Figure 1). We also found that, at the national level, vaccine 
uptake among PWID has increased over the period 2008 to 2014, with more than 75% of 
respondents reporting having received at least one dose of the vaccine in 2013-14.  
Importantly, among recent-onset injectors in Glasgow (who are prime targets for vaccination 
because they are less likely to be infected at the beginning of their injecting careers), there 
was a rise in the proportion of those vaccinated receiving at least 3 doses of the vaccine (to 
81% in 2013-14), up from 62% in 2001-2002.  
Incarceration was associated with an increased uptake of vaccination: 83% of PWID who 
had been incarcerated reported receiving the vaccine (compared to 64% among incarcerated 
individuals in 2001-02) [17], suggesting the vaccination programme is capturing an 
appreciable number of PWID who are imprisoned.  (Potential reasons for <100% coverage 
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among those who report having been incarcerated are: all new admissions are offered 
immunisation but some decline; a number of those committed to prison would have been 
released before vaccination could have been arranged; and some prisoners may have 
received the vaccine on admission but may simply have inaccurate recall).  Given the 
observational nature of this study, we cannot infer a causal association between the prison 
programme and our finding of increased vaccine uptake; however, prison is the most 
common site where PWID report receiving vaccinations (ranging from 40-50% in recent 
years) and, with no appreciable change in other settings, it is therefore unlikely that 
vaccination uptake rates of nearly 80% in the community would have been achieved without 
the prison programme. However, we do not know whether multiple doses from the vaccine 
schedule were received in prison, at other sites, or indeed across sites.  
Our analysis indicated that vaccination was associated with a reduced risk of infection. 
While this may be expected, it is nevertheless important to demonstrate this effect, given 
that vaccination may not necessarily be effective if it is delivered at the wrong time – for 
example, an individual may have acquired infection prior to receiving vaccination 
(particularly given that the highest risk of infection is in the first few years of injecting and 
therefore may occur before any contact with the prison service).   In this study, the 
prevalence of infection among those who report having been vaccinated was 8.3% for anti-
HBc and 0.9% for HBsAg. Potential reasons for this finding (other than becoming infected 
prior to vaccination) include: incomplete immunity due to not receiving the entire vaccine 
series; or potentially incorrect recall. Nevertheless, this finding highlights a potential gap for 
the prison programme as a public health strategy. 
We also found that incarceration was associated with an increased risk of infection, a finding 
that is consistent with other studies [11,24]. This observation is likely explained by the 
possibility that respondents may have become infected with HBV before imprisonment (and 
imprisonment may be a proxy for risk, i.e. individuals who end up in prison may also engage in 
more risk behaviours that expose them to HBV).  
This study established that the prevalence of anti-HBc and HBsAg is currently low among 
PWID in Scotland, particularly among those who had commenced injecting after the 
introduction of the prison programme. The overall prevalence of anti-HBc among Scottish 
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PWID (9%) is lower than that reported in other European countries (lower than 22 out of 25 
countries in a recent review) [1]; similarly the prevalence of HBsAg (0·9%) is lower than that 
reported by 15 out of 20 countries in another review [25]. The low levels of these HBV 
markers are consistent with data on acute HBV infections in Scotland, which have been 
declining and are at an all-time low. The number of acute infections reported annually has 
declined from 162 cases in 1999 (38% of whom were known to have injected drugs) to less 
than 20 cases in 2015 (none of which had injecting drug use indicated as a risk factor, 
although half had no risk information) [26].  The indication is that levels of HBV 
transmission among PWID in Scotland are very low indeed.  
Given the observational nature of this study, we cannot attribute the low levels of HBV 
infection solely to vaccination uptake: these are likely partly attributable to a range of other 
interventions that have been scaled up in Scotland since the early 1990s, including sterile 
injecting equipment provision and opiate substitute therapy. However, further evidence to 
support the effectiveness of prison vaccination is that there have been no outbreaks of HBV 
among PWID since the introduction of the prison programme (personal communication, 
David Goldberg), whereas there had been several outbreaks just prior to its introduction 
[27,28].  
Some key elements of the Scottish prison programme that likely contributed to its success 
were: not testing initially for evidence of previous exposure or immunity, adoption of the 
accelerated schedule (0, 1, and 2 months, and 6 month booster), and not testing for titre 
levels following vaccination. These elements helped to ensure the programme was easy to 
implement and achieved the greatest level of herd immunity possible in a transient 
population (personal communication, Alan Mitchell, former Head of Healthcare in the 
Scottish Prison Service). Additionally, all prisoners were encouraged to get immunised 
regardless of injecting history, which reduced stigma. A recent HBV transmission event in 
an English prison related to tattooing highlights the potential wider benefit of this approach 
[29]. 
In this paper, we have examined over 20 years of data on the uptake of HBV vaccination and 
recent data on markers of HBV infection among PWID recruited in Scotland in order to 
assess the potential impact of the Scottish HBV prison vaccination programme, established 
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in 1999. Given the UK is one of the few countries that have not implemented universal infant 
or adolescent HBV vaccination [6], there is a unique opportunity to evaluate this programme 
because the effects of the programme have not been contaminated by universal infant 
vaccination or catch-up programmes. However, the findings of this study are pertinent not 
just to other countries that have not implemented universal infant vaccination, but also to 
countries that have. This is because these programmes may not have had sufficient time to 
reach maturity. Assuming the average age of injecting debut is approximately 20 years, 
countries would have had to implement universal infant vaccination in 1996 or earlier, so 
that the birth cohorts that are now approaching the age of injecting onset are protected 
against HBV; however, less than a third of member states are in this situation [6]. Hepatitis B 
vaccines first became available in the early 1980s [30], so even the earliest adopters would 
only have coverage of cohorts up to age 35. Therefore, given the need for supplementary 
vaccination strategies to target PWID, and given that most countries have high rates of 
imprisonment of PWID [31], universal vaccination of prisoners presents an effective method 
of capturing this ‘hard-to-reach’ population. 
Limitations of this study 
The study sample for these analyses was drawn, in the main, from settings providing harm 
reduction services, which may under-represent PWID who are not in contact with such 
services. However, previous community-wide surveys undertaken in Glasgow showed that 
90% of PWID recruited from street sites had visited IEP services in the past six months [22] 
and we would therefore expect the study sample to reflect the great majority of PWID. 
Regarding the sensitivity of the laboratory tests, we may have missed anti-HBc and/or 
HBsAg infections (i.e. false negatives), which would result in an underestimate of the 
prevalence of these markers; however, these are likely to be few in number given that the 
prevalence of these markers is low. If the specificity of the anti-HBc assay on DBS is less than 
100% (as indicated by the confidence interval), there is a possibility of detecting false 
positives, in which case the prevalence of anti-HBc would be an overestimate; this is less of 
an issue for HBsAg, for which confirmatory testing was undertaken.  
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Because there are no validated tests for DBS, we did not measure immunity (i.e. anti-HBs 
positivity, generally considered to be a serological marker of immunity following 
vaccination) or markers of recent infection. Therefore, among individuals with no evidence 
of HBV markers, we do not know how many are immune from vaccination. Current HBV 
infection is not the same as HBV incidence and we therefore cannot make assertions about 
new HBV transmissions. Nevertheless, incidence is likely to be low given the small pool of 
current infection and the high uptake of HBV vaccination.  
Another limitation of this study is that the data on vaccination uptake are self-reported and 
may therefore be subject to poor recall or lack of understanding about which vaccinations 
were given. However, the findings are strengthened by the observation of a significant 
association between self-reported vaccination and HBV serology. 
The surveys did not consistently collect information on sexual risk behaviour and therefore 
these were not examined. Sexual transmission is a risk factor for HBV acquisition and 
therefore we cannot exclude the possibility of changes in sexual risk behaviour over time. 
However, some studies of PWID have not found a significant association between sexual 
risk behaviour and HBV [11,32], suggesting that sharing needles/syringes could be the 
predominant risk factor for acquiring HBV in this population.  
CONCLUSIONS 
In Scotland, the uptake of HBV vaccination among PWID has continued to increase since the 
introduction of universal prison vaccination, and levels of HBV infection among PWID are 
low. These findings point to the success of the universal prison vaccination approach in 
targeting PWID, one of the risk groups specified in UK vaccination policy. The prison-based 
approach should be considered by countries with absent or immature universal infant 
vaccination programmes in order to prevent transmission among PWID and reach their 
WHO elimination target (95% reduction in HBV incidence) by 2030. 
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Figure 1. Self-reported uptake of at least one dose of hepatitis B vaccine among people 
who inject drugs (PWID) surveyed in Glasgow and Scotland. 
*restricted to those who had commenced injecting within the previous 5 years and who had 
injected in the last two/six months 
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Table 1. Trends in the proportion of respondents reporting having been vaccinated, number of vaccine doses received, and where 
vaccinated, among people who inject drugs recruited via cross-sectional surveys in Glasgow/Scotland  
  Glasgow (recent-onset PWID)* All Scotland 
  
1993 1994 1999 2001-02 
2008 to 
2014 
combined 
χ
2
 for trend 
from 1993 
to 2014 2008-09 2010 2011-12 2013-14 
χ
2
 for trend 
from 2008 
to 2014 
Ever been vaccinated for HBV 
(1+ doses)** 
16% 
(26/166) 
19%  
(26/138) 
20%  
(55/272) 
52%  
(200/387) 
59% 
(379/639) 
χ
2
=193·5, 
p<0·001 
71%  
(1805/2537) 
72% 
(2161/3014) 
77% 
(1571/2049) 
77% 
(1744/2274) 
χ
2
=29·0, 
p<0·001 
             
Three or more doses of HBV 
vaccine received**† 
- - - 
62%  
(123/199) 
81% 
(301/372) 
χ
2
=24·8, 
p<0.001 
77% 
(1355/1757) 
84% 
(1794/2132) 
85% 
(1315/1541) 
83%  
(1424/1713) 
χ
2
=20·7, 
p<0·001 
             
Where 
vaccinated**†‡ 
Prison 
- - 
26% 
(12/47) 
56%  
(111/199) 
40% 
(152/379) 
χ
2
=0·7, 
p=0·402 
41% 
(736/1804) 
45% 
(973/2159) 
48% 
(755/1569) 
41% 
(714/1743) 
χ
2
=0·3, 
p=0·573 
General 
practice 
- - 
21% 
(10/47) 
13%  
(26/199) 
25% 
(95/379) 
χ
2
=5·4, 
p=0·021 
33% 
(592/1804) 
25% 
(544/2159) 
24% 
(378/1569) 
24% 
(424/1743) 
χ
2
=31·1, 
p<0·001 
 Drug 
treatment 
- - 
40%  
(19/47) 
23%  
(46/199) 
28% 
(106/379) 
χ
2
=0·4, 
p=0·539 
22% 
(388/1804) 
21% 
(449/2159) 
23% 
(366/1569) 
24% 
(417/1743) 
χ
2
=5·0, 
p=0·026 
 Hospital 
- - 
13% 
(6/47) 
7%  
(13/199) 
9% 
(34/379) 
χ
2
=0·02, 
p=0·882 
9% 
(166/1804) 
8% 
(179/2159) 
9% 
(148/1569) 
10% 
(182/1743) 
χ
2
=2·6, 
p=0·109 
 Other 
- - 
0%  
(0/47) 
2%  
(3/199) 
5% 
(18/379) 
N/A 6% 
(112/1804) 
8% 
(170/2159) 
6% 
(92/1569) 
7% 
(118/1743) 
χ
2
=0·03, 
p=0·854 
*Restricted to those with less than 5 years since injecting onset and who had injected in the last 2/6 months. See methods for details. 
**Excludes those who answered ‘don’t know’ to having been vaccinated and/or number of doses received and/or where vaccinated  
†Among those who reported ever being vaccinated 
‡Proportions may add up to >100% as individuals may be vaccinated in more than one location 
  
  
This article is protected by copyright. All rights reserved. 
Table 2. Trends and determinants in the uptake of hepatitis B vaccination among people who inject drugs surveyed at injecting equipment 
provision sites across Scotland in 2008-09, 2010, 2011-12 and 2013-14 (restricted to those who had been injecting for 10 years or less) 
  Proportion vaccinated for HBV*  OR for HBV vaccine uptake 
  2008-09 2010 2011-12 2013-14 Total Univariable P value Multivariable P value 
Survey 2008-09 69% (940/1371) - - - 
70% (3197/4577) 
Ref  Ref  
  2010 - 70% (1020/1462) - - 1·06 (0·90-1·24) 0·488 1·05 (0·91-1.214) 0·540 
  2011-12 - - 71% (635/898) - 1·11 (·.92-1·33) 0·277 1·12 (0·92-1·36) 0·266 
  2013-14 - - - 71% (602/846) 1·13 (0·94-1·36) 0·197 1·19 (1.02-1·40) 0·028 
           
Gender Male 70% (646/922) 71% (695/977) 72% (431/602) 70% (367/521) 71% (2139/3022) Ref  Ref  
  Female 65% (289/443) 67% (323/481) 69% (203/295) 72% (231/320) 68% (1046/1539) 0·88 (0·77-1·00) 0·050 1·01 (0·75-1·37) 0·937 
           
Age at interview ≤25 years 68% (235/348) 65% (222/340) 64% (110/171) 68% (112/165) 66% (679/1024) Ref  Ref  
  26-30 years 69% (304/439) 75% (337/447) 75% (187/249) 75% (168/224) 73% (996/1359) 1·39 (1·17-1·66) <0·001 1·09 (0·84-1·43) 0·502 
  31-35 years 70% (223/319) 74% (257/349) 77% (179/233) 74% (162/218) 73% (821/1119) 1·40 (1·16-1·69) <0·001 1·03 (0·74-1·45) 0·858 
  >35 years 67% (178/265) 63% (204/326) 65% (159/245) 67% (160/239) 65% (701/1075) 0·95 (0·80-1·14) 0·596 0·76 (0·56-1.02) 0·070 
           
Time since onset of 
injecting 
<2 years 48% (129/268) 53% (169/320)  50% (83/166) 60% (99/166) 52% (480/920) Ref  Ref  
2-4 years 68% (257/376) 67% (262/392) 69% (179/261) 69% (161/233) 68% (859/1262) 1·95 (1·64-2·33) <0·001 1·40 (1·22-1·62) <0·001 
  5-9 years 76% (554/727) 79% (589/750) 79% (373/471) 77% (342/447) 78% (1858/2395) 3·17 (2·70-3·73) <0·001 1·84 (1·55-2·19) <0·001 
           
Ever prescribed 
methadone 
No 47% (118/249) 41% (94/231) 42% (55/130) 49% (79/161) 45% (346/771) Ref  Ref  
Yes 73% (822/1122) 75% (926/1231) 76% (579/767) 76% (162/684) 75% (2849/3804) 3·66 (3·12-4·30) <0·001 2·95 (2·03-4.30) <0·001 
           
Ever incarcerated** No 57% (404/712) 57% (421/736) 58% (278/479) 59% (250/421) 58% (1353/2348) Ref  Ref  
  Yes 81% (535/657) 83% (598/725) 85% (355/417) 83% (349/419) 83% (1837/2218) 3·55 (3·09-4·07) <0·001 2·91 (2·23-3·79) <0·001 
*At least one dose of HBV vaccination. Excludes those who answered ‘don’t know’ 
**Since onset of injecting 
  
  
This article is protected by copyright. All rights reserved. 
Table 3. Association between HBV vaccination and ever infection (anti-HBc positivity) 
among people who inject drugs recruited at sites that provide injecting equipment in 
Scotland, 2013-14.  
   Anti-HBc positive OR for anti-HBc positivity 
  N n % Univariable P value 
Multivariable 
(n=2286) P value 
Ever vaccinated 
for HBV  
 
No 524 60 11.5 Ref  Ref  
Yes 1729 143 8.3 0·70 (0·51-0·96) 0·027 0·60 (0·37-0·97) 0·037 
Don't know 69 7 10.1 0·87 (0·38-2·00) 0·748 1·19 (0·63-2·27) 0·589 
         
Gender Male 1601 160 10.0 Ref   Ref   
Female 707 49 6.9 0·67 (0·48-0·94) 0.019  1·04 (0·68-1·58) 0·864 
         
Age <35 988 36 3.6 Ref  Ref  
 35+ 1330 173 13.0  3.91 (2.70-5.66) <0.001 2.48 (1.93-3.17) <0.001 
         
Time since onset 
of injecting 
<10 years 872 23 2.6 Ref  Ref  
10+ years 1441 186 12.9  5.47 (3.52-8.51)  <0.001  3.33 (1.83-6.06)  <0.001 
         
Ever incarcerated* No 800 37 4.6 Ref  Ref  
Yes 1501 170 11.3 2·63 (1·83-3·80) <0.001 2.10 (1·34-3.31) 0·001 
OR: odds ratio 
*Since onset of injecting 
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Table 4. Association between HBV vaccination and current infection (anti-HBc and 
HBsAg positivity) among people who inject drugs recruited at sites that provide injecting 
equipment in Scotland, 2013-14*. 
   Current infection OR for current infection 
  N n % Univariable P value 
Multivariable 
(n=2101) P value 
Ever vaccinated for 
HBV  
 
No 472 8 1.7 Ref  Ref  
Yes 1600 14 0.9 0·51 (0·21-1·23) 0·134 0·40 (0·16-0·97) 0·043 
Don't know 62 0 0.0 N/A N/A N/A N/A 
         
Gender 
  
Male 1461 20 1.4 Ref   Ref   
Female 660 2 0.3 0·22 (0·05-0·94) 0·041 0·34 (0·08-1·48) 0·335 
         
Age 
  
≤35 957 5 0.5 Ref  Ref  
>35 1174 17 1.4 2·80 (1·03-7·61) 0·044 1·52 (0·52-4·50) 0·447 
         
Time since onset 
of injecting 
<10 years 852 3 0.4 Ref  Ref  
10+ years 1274 19 1.5 4·28 (1·26-14·52) 0·019 2·61 (0·69-9·88) 0·158 
         
Ever 
incarcerated** 
No 766 3 0.4 Ref  Ref  
Yes 1349 18 1.3 3·44 (1·01-11·71) 0·048 2·43 (0·68-8·70) 0·172 
         
Recruitment 
region 
GG&C 767 11 1.4 1·79 (0·77-4·16) 0·173 1·28 (0·53-3·07) 0·586 
Rest of 
Scotland 
1367 11 0.8 Ref  Ref  
GG&C: Greater Glasgow & Clyde; OR: odds ratio 
*Individuals with past infection (i.e. anti-HBc positive and HBsAg negative, n=19) were 
excluded, thus the comparison group was anti-HBc negatives  
**Since onset of injecting 
